NUsurface

Executive Summary

NUsurface is a privately held medical device company headquartered in Memphis, Tennessee, specializing in orthopedic implants for the knee. The company is best known for its NUsurface® Meniscus Implant, a polymer-based, non-absorbable device designed to replace the medial meniscus in patients with meniscal insufficiency. Currently classified as an investigational device in the United States, the implant has received CE mark approval in Europe, where it has been used clinically. NUsurface aims to address the significant unmet need for meniscal repair, offering a potential alternative to meniscectomy or transplantation. The device is intended for patients with prior meniscectomy who experience persistent knee pain and dysfunction. The company has been developing this technology since its founding in 2004 and is actively pursuing regulatory clearance in the US through clinical trials. Key competitive advantages include a minimally invasive implantation procedure, avoidance of donor tissue limitations, and a design that mimics natural meniscus function. However, the company faces challenges related to regulatory hurdles, clinical evidence requirements, and market adoption. With the aging population and increasing incidence of knee injuries, the addressable market is substantial. NUsurface's success hinges on securing FDA approval and demonstrating long-term clinical efficacy and safety.

Upcoming Catalysts (preview)

• Q2 2027Completion of US Pivotal Trial Enrollment80% success
• Q1 2028FDA Pre-Market Approval Submission60% success
• Q4 2026Strategic Partnership or Licensing Deal50% success